

REGISTER OF INTERESTS

SIGN guideline: Management of migraine – 2022 update

Published: 29 Sept 22

21 April 2022

	Financial		Non-financial		Non-personal	Date received by SIGN Executive	Action
	Specific	Non-Specific	Specific	Non-Specific			
CHAIR							
Callum Duncan, Consultant Neurologist, NHS Grampian	None	None	<p>Advised on Erenumab Consultation – SMC – ceased Dec 2018.</p> <p>Advised on Fremanezumab Consultation – SMC – ceased Sept 2019.</p> <p>Advised on Galcenezumab Consultation – SMC – ceased Nov 2020.</p> <p>Contributing to systematic review on preventative treatment for Chronic Migraine –</p>	<p>Advised on Gammacore for Cluster Headache – SHTG – ceased Dec 2020.</p>	None	18.4.22	<p>Group made aware of interests.</p> <p>No restriction on participation.</p>

REGISTER OF INTERESTS

SIGN guideline: Management of migraine – 2022 update

Published: 29 Sept 22

21 April 2022

			<p>University of Warwick – current.</p> <p>Contributing to book chapter on evidence based preventative treatment for migraine - Handbook of Clinical Neurology – current.</p> <p>Chair National Headache Pathway Group - Modernising Patient Pathways Program – current.</p>				
GUIDELINE DEVELOPMENT GROUP MEMBER							
Javier Artal, Consultant Neurologist, Raigmore	Nothing declared	Nothing declared	Nothing declared	Advisory board on sativex – GW –	Nothing declared	20.4.22	Group made aware of interests.

REGISTER OF INTERESTS

SIGN guideline: Management of migraine – 2022 update

Published: 29 Sept 22

21 April 2022

Hospital, NHS Highland				ceased 2021. Training session and Advisory board on ponesimod for MS – Janssen – ceased 2021. Advisory board on ozanimod for MS – BMS – ceased 2021. Advisory board on ponesimod for MS – Novartis – ceased 2021. Advisory board on			No restriction on participation.
------------------------	--	--	--	---	--	--	----------------------------------

REGISTER OF INTERESTS

SIGN guideline: Management of migraine – 2022 update

Published: 29 Sept 22

21 April 2022

				ongentys, ontacapone for PD – Bial – ceased 2020.			
Arlene Coulson, Lead Clinical Pharmacist, NHS Tayside	None	Advisory board - Novartis	None	None	None	25.4.22	No action required.
Dr Krishna Dani, Consultant Neurologist, NHS GGC	Member of Educational Steering Committee – Allergan - One off meeting December 2020 - (not discussing the anti CGRP drugs but rather Botox, an alternative treatment). Chair Chronic Migraine Webcast – Allergan - One off meeting March 2021 - (not discussing the anti CGRP drugs but rather Botox, an alternative treatment).	None	Advised on Fremanezumab consultation – SMC – ceased Oct 2019. Advised on Galcanezumab consultation – SMC – ceased 2020.	Advised on Gammacore for Cluster Headache – SHTG – ceased Dec 2020 - (topic was cluster headache, not migraine)	None	9.4.22	Group made aware of interests. Participation agreed by SIGN senior management and group chair, as specialist expertise is required.

REGISTER OF INTERESTS

SIGN guideline: Management of migraine – 2022 update

Published: 29 Sept 22

21 April 2022

	<p>Funding for trip to International Headache Congress, Dublin, Ireland – Novartis - One off Meeting September 2019.</p> <p>Kings College Headache Debating Meeting Travel and accommodation arranged by Novartis -October 2019.</p>						
Shona Scott, Consultant Neurologist, NHS Lothian/GMC	None	<p>Speaker Fee – Arvelle – 2020.</p> <p>Very small share holding – AstraZeneca</p>	None	Advisory board/round table – Arvelle – 2021	None	2.5.22	Group made aware of interests.
Sandeep Sharma, General Practitioner & GP Partner	None	None	None	None	None	25.4.22	No action required

REGISTER OF INTERESTS

SIGN guideline: Management of migraine – 2022 update

Published: 29 Sept 22

21 April 2022

Katrine West, Patient Representative	None	None	My only participation in an organisation is my involvement as a patient representative for the SIGN migraine guidelines.	None	None	26.4.22	No action required.
--	------	------	--	------	------	---------	---------------------